CAR-modified gp100-specific T Cells (CAR-gp100STs) Solutions

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs team prioritizes creativity, diverse perspectives, and tenacity to expedite our goal of bringing life-changing CAR-T therapies to the market. Our team is built on the foundation of innovation and scientific discovery, and all employees of the company will be passionate about providing CAR-modified gp100-specific T-cell services. Welcome to inquiry!

Introduction to T Cell Therapy

The cytotoxic effect of T lymphocytes on antigens has been harnessed in the battle against cancer, making it a prominent research focus in tumor therapy. From the perspective of molecular and cell biology, significant advancements have been made in our understanding of T cells, leading to the development of new strategies to combat cancer such as immune checkpoints, adoptive cell therapy, and cancer vaccines. Recently, a novel therapeutic technique that combines the adoptive transfer of autologous T cells with a cancer vaccine strategy has begun to gain widespread attention. Studies have shown that the use of vaccine-specific co-stimulation of CAR T cells can improve anti-tumor activity.

Fig.1 Schemetic Diagram of Lentiviral Vector Used For GPA7-28z CAR Expression. (Zhang, et al., 2014) Fig.1 Schematic Diagram of Lentiviral Vector Used For GPA7-28z CAR Expression.¹

CAR-modified gp100-specific T Cells (CAR-gp100STs) Solutions

In Creative Biolabs, we're building a future in virus-based vaccine-boosting CAR-T Cell therapies that are effective and safe for the treatment of solid and liquid tumors. In our labs, the vaccine is highly expressed on the surface of antigen presentation cells (APCs) as a homologous ligand of conventional CAR-T cells. These virus-based vaccines can further induce tumor-associated cytokine production and improve the expansion and persistence of CAR-T cells.

To improve the translational potential of vaccine-based CAR-T therapies, it will be important for us to design vaccines that retarget bispecific CAR-T cells. As a result, we have developed a CAR-modified gp100-specific T cells (CAR-gp100STs) development platform for our worldwide customers. We have constructed a bispecific T cell system to express tumor-associated antigen CAR-specific T cells and melanocyte protein (gp100) TCR-specific T cells, respectively. This bispecific T cell system can be further combined with recombinant vaccinia virus expressing gp100 to enhance the efficacy of solid tumor therapy.

Advantages

A novel CAR-T cell therapy that can mediate the eradication of several different histological solid tumors has been identified.
While maintaining the activation and expansion of CAR T cells, and improving their localization to tumors.
CAR-T cells are activated against large solid tumors in a homologous autoantigen setting.
A TCR-like CAR has been designed to redirect human T cells specifically to the melanoma-associated gp100/HLA complex.

Fig.2 Specific Vaccinia Virus And Dual-specific T Cells Are Required For Optimal Antitumor Activity.²

How We Can Assist Your Project

Over the past few decades, Creative Biolabs has successfully established a leading T-cell therapy platform, paving the way for the next frontier in oncology research. Since then, Creative Biolabs has focused its full attention on the use of conventional, modified, and customized CAR-T to achieve safe, effective treatment of liquid and solid tumors. Currently, Through its patented CAR-T and vaccine technology, we have discovered a gp100-specific CAR-T-based cell therapy platform. It is designed to enable the immune system to quickly and fully rearm to fight cancer, particularly solid tumors. we can offer a comprehensive CAR-gp100STs solution, ranging from CAR design, T cell activation, virus packaging, CAR T cell expansion to CAR T cell quality control.

Advanced and efficient molecular screening platform for CAR candidates
GMP-grade cytokines activate CAR T cells with higher safety
High active target proteins support scFv screening and CAR-positive detection
Serum-free medium supports large-scale production of CAR-T cells
GMP-grade nucleases guarantee a high-quality virus production process
Professional knowledge and staff to ensure CAR-T quality

Through the complementary application of biological insights and technological advances, Creative Biolabs aims to unlock the transformative potential of CAR-T therapies. Our proprietary CAR-gp100STs technology can further enhance anti-tumor activity and persistence while retaining conventional CAR-T functionality, opening up opportunities for novel cell therapies for the treatment of solid tumors. If you are interested in our services, please do not hesitate to contact us for more details.

References

Zhang, Ge, et al. "Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor." Scientific reports 4.1 (2014): 3571.
Slaney, Clare Y., et al. "Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting." Clinical cancer research 23.10 (2017): 2478-2490.